HOWL — Werewolf Therapeutics, Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1785530 ·
Last close
$0.88
Market Cap
$42.93M
52W High
$1.05
52W Low
$0.27
ADV30
12,949,385
Next earnings
Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 21,000,000 7,158,000 3,670,000 24,155,000 21,987,000 7,863,000
Mar 2026 0 -13,271,000 -13,532,000 58,022,000 46,450,000 45,820,000
Dec 2025 0 -9,418,000 -8,381,000 69,396,000 57,050,000 44,591,000
Sep 2025 0 -15,726,000 -16,370,000 79,627,000 65,711,000 50,013,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-30,148,000
Investing CF
$0
Financing CF
$6,028,000
CapEx
$-123,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.76
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$-485,272,000
Inventory
Receivables
$0
ST Investments
EBIT TTM
$-30,060,000
Pretax Income TTM
$-34,613,000
Interest Exp TTM
$4,553,000
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$21,000,000
EBITDA
$-21,921,000
Free Cash Flow
$-12,233,750
Enterprise Value
$20,464,284
Total Cash
$21,987,000
Total Debt
$0
Shares Out
48,599,066
Trailing EPS
$-0.73
Book Value
$0.34
ROE
-119.9%
ROA
-27.4%
Div Yield

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -60,677,000 -60,822,000 69,396,000 44,591,000 -60,292,000
Dec 2024 1,885,000 -73,594,000 -70,515,000 126,929,000 53,539,000 -56,188,000
Dec 2023 19,943,000 -40,503,000 -37,368,000 174,833,000 63,459,000 -32,612,000
Dec 2022 16,401,000 -56,056,000 -53,810,000 160,245,000 37,908,000 -40,596,000
Dec 2021

TTM Snapshot

Revenues TTM
$8,541,000
NetIncome TTM
$-50,659,000
OpCashFlow TTM
$0
Assets (Latest)
$126,929,000
Forward EPS
$-0.59

Peers — same industry

TickerNameMarket CapLastDaily %
CNTX Context Therapeutics Inc. $42.76M $0.47
IXHL Incannex Healthcare Inc. $43.31M $3.62
EDSA Edesa Biotech, Inc. $42.42M $4.40
KPTI Karyopharm Therapeutics Inc. $42.19M $1.86
VERU VERU INC. $44.16M $2.59

News headlines (Yahoo Finance, 1h cache)

Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News
2026-08-21 17:51 · Yahoo
Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing
2026-08-21 13:26 · Yahoo
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement
2026-08-21 12:00 · Yahoo
Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates
2026-07-31 11:00 · Yahoo
Here's Why We're A Bit Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Situation
2026-05-14 11:23 · Yahoo
Werewolf Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Updates
2026-05-07 20:05 · Yahoo
Sector Update: Healthcare Stocks Advance in Afternoon Trading
2026-08-21 17:43 · Yahoo
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement
2026-08-21 12:00 · Yahoo
JAZZ Q2 Earnings Miss, Sales Beat, Stock Jumps on Raised '26 View
2026-08-04 17:42 · Yahoo
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates
2026-03-27 11:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.